Los Angeles Capital Management LLC Has $1.87 Million Stake in Collegium Pharmaceutical, Inc. $COLL

Los Angeles Capital Management LLC lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 39.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 40,441 shares of the specialty pharmaceutical company’s stock after selling 26,799 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $1,872,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Massachusetts Financial Services Co. MA raised its position in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after purchasing an additional 518,721 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Collegium Pharmaceutical by 161.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock valued at $23,692,000 after buying an additional 316,109 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after buying an additional 242,310 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Collegium Pharmaceutical by 237.9% in the third quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock valued at $11,216,000 after buying an additional 225,679 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have commented on COLL. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.85% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Trading Up 1.2%

NASDAQ COLL opened at $34.80 on Thursday. Collegium Pharmaceutical, Inc. has a 12 month low of $29.08 and a 12 month high of $50.79. The stock has a 50-day simple moving average of $33.94 and a 200 day simple moving average of $40.65. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $1.13 billion, a PE ratio of 17.06 and a beta of 0.74.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.49 earnings per share. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.